Cargando…

Impact of a digital web-based asthma platform, a real-life study

BACKGROUND: Digital health technology (DHT) is a growing area in the treatment of chronic diseases. Study results on DHT’s effect on asthma control have been mixed, but benefits have been seen for adherence, self-management, symptoms, and quality of life. The aim was to evaluate the impact of an int...

Descripción completa

Detalles Bibliográficos
Autores principales: Genberg, Emma M., Viitanen, Hilkka T., Mäkelä, Mika J., Kautiainen, Hannu J., Kauppi, Paula M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177708/
https://www.ncbi.nlm.nih.gov/pubmed/37173716
http://dx.doi.org/10.1186/s12890-023-02467-8
_version_ 1785040690784239616
author Genberg, Emma M.
Viitanen, Hilkka T.
Mäkelä, Mika J.
Kautiainen, Hannu J.
Kauppi, Paula M.
author_facet Genberg, Emma M.
Viitanen, Hilkka T.
Mäkelä, Mika J.
Kautiainen, Hannu J.
Kauppi, Paula M.
author_sort Genberg, Emma M.
collection PubMed
description BACKGROUND: Digital health technology (DHT) is a growing area in the treatment of chronic diseases. Study results on DHT’s effect on asthma control have been mixed, but benefits have been seen for adherence, self-management, symptoms, and quality of life. The aim was to evaluate the impact of an interactive web-based asthma treatment platform on asthma exacerbations and health care visits. METHODS: In this real-life study, we retrospectively collected data on adult patients registered on a web-based interactive asthma treatment platform between December 2018 and May 2021. Patients who activated their accounts were active users, and patients who did not were inactive users and considered as controls. We compared the number of exacerbations, total number of exacerbation events defined as the sum of oral corticosteroid (OCS) and antimicrobial courses, emergency room visits, hospitalizations, and asthma-related health care visits before and one year after the registration on the platform. Statistical tests used included the t-test, Pearson’s chi-square test and Poisson regression models. RESULTS: Of 147 patients registered on the platform, 106 activated their accounts and 41 did not. The active users had significantly fewer total number of exacerbation events (2.56 per person years, relative decline 0.78, 95% CI 0.6 to 1.0) and asthma-related health care visits (2.38 per person years, relative decline 0.84, 95% CI 0.74 to 0.96) than before registration to the platform, whereas the reductions in health care visits and the total number of exacerbation events were not significant in the inactive users. CONCLUSIONS: An interactive web-based asthma platform can reduce asthma-related health care visits and exacerbations when used actively.
format Online
Article
Text
id pubmed-10177708
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101777082023-05-14 Impact of a digital web-based asthma platform, a real-life study Genberg, Emma M. Viitanen, Hilkka T. Mäkelä, Mika J. Kautiainen, Hannu J. Kauppi, Paula M. BMC Pulm Med Research BACKGROUND: Digital health technology (DHT) is a growing area in the treatment of chronic diseases. Study results on DHT’s effect on asthma control have been mixed, but benefits have been seen for adherence, self-management, symptoms, and quality of life. The aim was to evaluate the impact of an interactive web-based asthma treatment platform on asthma exacerbations and health care visits. METHODS: In this real-life study, we retrospectively collected data on adult patients registered on a web-based interactive asthma treatment platform between December 2018 and May 2021. Patients who activated their accounts were active users, and patients who did not were inactive users and considered as controls. We compared the number of exacerbations, total number of exacerbation events defined as the sum of oral corticosteroid (OCS) and antimicrobial courses, emergency room visits, hospitalizations, and asthma-related health care visits before and one year after the registration on the platform. Statistical tests used included the t-test, Pearson’s chi-square test and Poisson regression models. RESULTS: Of 147 patients registered on the platform, 106 activated their accounts and 41 did not. The active users had significantly fewer total number of exacerbation events (2.56 per person years, relative decline 0.78, 95% CI 0.6 to 1.0) and asthma-related health care visits (2.38 per person years, relative decline 0.84, 95% CI 0.74 to 0.96) than before registration to the platform, whereas the reductions in health care visits and the total number of exacerbation events were not significant in the inactive users. CONCLUSIONS: An interactive web-based asthma platform can reduce asthma-related health care visits and exacerbations when used actively. BioMed Central 2023-05-12 /pmc/articles/PMC10177708/ /pubmed/37173716 http://dx.doi.org/10.1186/s12890-023-02467-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Genberg, Emma M.
Viitanen, Hilkka T.
Mäkelä, Mika J.
Kautiainen, Hannu J.
Kauppi, Paula M.
Impact of a digital web-based asthma platform, a real-life study
title Impact of a digital web-based asthma platform, a real-life study
title_full Impact of a digital web-based asthma platform, a real-life study
title_fullStr Impact of a digital web-based asthma platform, a real-life study
title_full_unstemmed Impact of a digital web-based asthma platform, a real-life study
title_short Impact of a digital web-based asthma platform, a real-life study
title_sort impact of a digital web-based asthma platform, a real-life study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177708/
https://www.ncbi.nlm.nih.gov/pubmed/37173716
http://dx.doi.org/10.1186/s12890-023-02467-8
work_keys_str_mv AT genbergemmam impactofadigitalwebbasedasthmaplatformareallifestudy
AT viitanenhilkkat impactofadigitalwebbasedasthmaplatformareallifestudy
AT makelamikaj impactofadigitalwebbasedasthmaplatformareallifestudy
AT kautiainenhannuj impactofadigitalwebbasedasthmaplatformareallifestudy
AT kauppipaulam impactofadigitalwebbasedasthmaplatformareallifestudy